1.Role of selectin in lung injury in rabbits with diabetic ketoacidosis
Xiaojun GU ; Jiabao CHANG ; Xiaoyun ZHU ; Guoqing YIN
Chinese Journal of Pathophysiology 2000;0(12):-
AIM: To study the effect of selectin on lung injury in rabbits with diabetic ketoacidosis(DKA). METHODS: 12 male New Zealand rabbits were divided into experimental group (DK groups, intravenous injection of streptozocin and alloxan monohydroate, n =6) and normal control group (received same dose of saline, n =6). After 72 hours, all the animals were killed and blood and lung tissue were collected. Blood gases, expressions of selectin-P and selectin-L were detected. RESULTS: The expression of selectin in DK group were higher than that in NS group. CONCLUSION: These results indicate that selectin expression may play an important role in lung injury during diabetic ketoacidosis.
2.Clinical study on teibivudine combined with adefuvir dipivoxii in the treatment of Hepatitis B patients with decompensated cirrhosis
Li LI ; Weiwei DAI ; Yanhong FENG ; Jiabao CHANG ; Jie QIU ; Weifeng WU
Chinese Journal of Primary Medicine and Pharmacy 2012;19(4):485-486
Objective To observe the effect of telbivudine combined with adefuvir dipivoxil in the treatment of Hepatitis B patients with decompensated cirrhosis.Methods 56 Hepatitis B patients with decompensated cirrhosis were divided into two groups:treatment group (30 cases) and control group (26 cases).During 24 weeks,the control group received adefuvir dipivoxil( 10mg daily),supportive and symptomatic treatments,while the treatment group received telbivudine therapy(600mg daily) combiled with adefuvir dipivoxil ( 10mg daily) based on the regular treatments.After 24 weeks,the effect was observed and compared between the two groups.Results After treatment,the biochemical markers,Child-Pugh score of the treatment group was (33.2 ± 13.8) μmol/L,(44.5 ± 16.4) U/L,(36.1 ±1.5) g/L,(6.1 ± 1.8) points,respectively,and was better than those of the control group[ (71.8 ±18.6) μ mol/L,(89.9 ±44.9) U/L,(29.7 ± 1.3)g/L,(8.1 ±2.2) points] (t=15.32,15.20,23.37,6.09,all P<0.05) ;HBV-DNA negative rate,HBeAg seroconversion rates of the treatment group was 93.3% (28/30),43.3%(13/30),and was higher than that of the control group[76.9% (20/26),7.6% (2/26) ] (x2 =4.87,9.08,all P<0.05).Conclusion Telbivudine combined with adefuvir dipivoxil was effective and safe for the treatment of Hepatitis B patients with decompensated cirrhosis.